These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 14657626)

  • 21. Comparative expression profile of CD10 and cyclin D1 in cutaneous histiocytofibroma and dermatofibrosarcoma.
    Kouki N; Ben Rejeb S; Cherif I; Ghozzi A; Chelly I; Bellil K; Haouet S
    J Immunoassay Immunochem; 2021 Jul; 42(4):347-358. PubMed ID: 33444077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fibrohistiocytic skin tumors].
    Hügel H
    J Dtsch Dermatol Ges; 2006 Jul; 4(7):544-55. PubMed ID: 16827912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Benign cellular fibrous histiocytoma with erosion of the phalanx].
    Kurzen H; Hartschuh W
    Hautarzt; 2003 May; 54(5):453-6. PubMed ID: 12719866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous and subcutaneous fibrohistiocytic tumors of intermediate malignancy: an update.
    Billings SD; Folpe AL
    Am J Dermatopathol; 2004 Apr; 26(2):141-55. PubMed ID: 15024197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
    Kubo M; Ihn H; Yamane K; Tamaki K
    Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin.
    Lee CS; Chou ST
    Pathology; 1998 Aug; 30(3):272-5. PubMed ID: 9770192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical analysis of CXCR4 expression in fibrohistiocytic tumors.
    Toyozawa S; Yamamoto Y; Ishida Y; Kondo T; Nakamura Y; Furukawa F
    Acta Histochem Cytochem; 2010 May; 43(2):45-50. PubMed ID: 20514291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study of collagen refractility in dermatofibroma and dermatofibrosarcoma protuberans using diffractive microscopy.
    Brailsford C; Khamdan F; Dirr MA; Sagut P; Nietert PJ; Elston D
    J Cutan Pathol; 2024 Apr; 51(4):306-310. PubMed ID: 38124386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Immunological Roles of Periostin/Tumor-Associated Macrophage Axis in Development of Dermatofibrosarcoma Protuberans.
    Fujimura T; Kakizaki A; Sato Y; Tanita K; Furudate S; Aiba S
    Anticancer Res; 2017 Jun; 37(6):2867-2873. PubMed ID: 28551623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34.
    Aiba S; Tabata N; Ishii H; Ootani H; Tagami H
    Br J Dermatol; 1992 Aug; 127(2):79-84. PubMed ID: 1382538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression of connective tissue growth factor gene in cutaneous fibrohistiocytic and vascular tumors.
    Igarashi A; Hayashi N; Nashiro K; Takehara K
    J Cutan Pathol; 1998 Mar; 25(3):143-8. PubMed ID: 9550312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical fibroxanthoma and malignant fibrous histiocytoma of the skin.
    Rizzardi C; Angiero F; Melato M
    Anticancer Res; 2003; 23(2C):1847-51. PubMed ID: 12820468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
    Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
    Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. nm23 protein expression and p53 immunoreactivity in cutaneous fibrohistiocytic tumors.
    Lee CS; Clarke RA; Tran KT; Kearsley JH; Chou ST
    Pathology; 1999 May; 31(2):123-6. PubMed ID: 10399167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
    Abdaljaleel MY; North JP
    Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiomatoid malignant fibrous histiocytoma: flow cytometric DNA analysis of six cases.
    el-Naggar AK; Ro JY; Ayala AG; Hinchey WW; Abdul-Karim FW; Batsakis JG
    J Surg Oncol; 1989 Mar; 40(3):201-4. PubMed ID: 2537444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant fibrous tumors.
    Stadler FJ; Scott GA; Brown MD
    Semin Cutan Med Surg; 1998 Jun; 17(2):141-52. PubMed ID: 9669607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ETS-related Gene (ERG) is Differentially Expressed in Dermatofibroma (Fibrous Histiocytoma) as Compared With Dermatofibrosarcoma Protuberans and Hypertrophic Scars: A Pilot Immunohistochemical Study.
    Hengy M; Veenstra J; Perry K; Ozog DM; Friedman BJ
    Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):453-458. PubMed ID: 35510745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
    Kahn HJ; Fekete E; From L
    Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. S100A6 expression in fibrohistiocytic lesions.
    Fullen DR; Reed JA; Finnerty B; McNutt NS
    J Cutan Pathol; 2001 May; 28(5):229-34. PubMed ID: 11401666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.